AM-1220 is a drug that acts as a potent and moderately selective agonist for the cannabinoid receptor CB1 with around 19x selectivity for CB1 over the related CB2 receptor. It was originally invented in the early 1990s by a team led by Thomas D’Ambra at Sterling Winthrop but has subsequently been researched by many others most notably the team led by Alexandros Makriyannis at the University of Connecticut.
This page contains content from the copyrighted Wikipedia article "AM-1220"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
